This paper reports a case of a rare patient with inherited thrombophilia leading to mesenteric venous thrombosis and secondary small bowel obstruction. The diagnosis of the patient was confirmed through multidisciplinary team collaboration, and the intestinal obstruction was finally relieved through small bowel endoscopic treatment and surgical treatment. This paper also discusses the differential diagnosis and treatment of small bowel stricture lesions for peer reference.

Objective:To investigate the use of quantitative flow ratio(QFR) for selecting suitable anastomosis targets of radial artery in coronary artery bypass grafting.Methods:From January 2019 to June 2023, clinical data of patients undergoing coronary artery bypass grafting with using radial artery obtained from Beijing Anzhen Hospital were retrospectively collected. A total of 186 patients were included in this study, including 175 males and 11 females. The average age was(54.26±7.91) years, ranging from 34 to 70 years. They were divided into study group(n=46) and control group(n=140) according to whether QFR was examined before operation. The distal radial artery in the study group was anastomosed to a non-LAD artery with the lowest QFR value, while in the control group was randomly anastomosed to the most important non-LAD artery with the anatomic stenosis greater than 75%. All patients were followed up. The endpoint event was major adverse cardiovascular events(MACE) and radial grafts stenosis/occlusion. The preoperative baseline data, perioperative indexes and follow-up were analyzed and compared.Results:There was no significant difference in preoperative baseline data between the two groups. The pulse index(PI) in the study group was significantly lower than that in the control group(1.88±0.45 vs. 2.11±0.61, P<0.05). There were no serious perioperative complications in both groups. All patients survived and were discharged from hospital. The average follow-up time was 30 months. There were no significant differences in cardiogenic death, stroke, recurrent myocardial infarction, and revascularization between the two groups. The rate of recurrent angina in the study group was significantly lower than that in the control group(8.7% vs. 22.1%, P<0.05). The complete patency rate of radial graft in the study group was significantly higher than that in the control group(96.4% vs. 86.0%, P<0.05), the occlusion rate was significantly lower than that in the control group(0 vs. 9.4%, P<0.05), and the stenosis rate had no significant difference between two groups. Conclusion:QFR can clarify the functional changes of coronary blood flow, select suitable anastomosis target for radial graft, reduce the occurrence of competing flow, and then improve the patency rate and clinical prognosis.

This paper reports a case of a rare patient with inherited thrombophilia leading to mesenteric venous thrombosis and secondary small bowel obstruction. The diagnosis of the patient was confirmed through multidisciplinary team collaboration, and the intestinal obstruction was finally relieved through small bowel endoscopic treatment and surgical treatment. This paper also discusses the differential diagnosis and treatment of small bowel stricture lesions for peer reference.

Objective:To investigate the use of quantitative flow ratio(QFR) for selecting suitable anastomosis targets of radial artery in coronary artery bypass grafting.Methods:From January 2019 to June 2023, clinical data of patients undergoing coronary artery bypass grafting with using radial artery obtained from Beijing Anzhen Hospital were retrospectively collected. A total of 186 patients were included in this study, including 175 males and 11 females. The average age was(54.26±7.91) years, ranging from 34 to 70 years. They were divided into study group(n=46) and control group(n=140) according to whether QFR was examined before operation. The distal radial artery in the study group was anastomosed to a non-LAD artery with the lowest QFR value, while in the control group was randomly anastomosed to the most important non-LAD artery with the anatomic stenosis greater than 75%. All patients were followed up. The endpoint event was major adverse cardiovascular events(MACE) and radial grafts stenosis/occlusion. The preoperative baseline data, perioperative indexes and follow-up were analyzed and compared.Results:There was no significant difference in preoperative baseline data between the two groups. The pulse index(PI) in the study group was significantly lower than that in the control group(1.88±0.45 vs. 2.11±0.61, P<0.05). There were no serious perioperative complications in both groups. All patients survived and were discharged from hospital. The average follow-up time was 30 months. There were no significant differences in cardiogenic death, stroke, recurrent myocardial infarction, and revascularization between the two groups. The rate of recurrent angina in the study group was significantly lower than that in the control group(8.7% vs. 22.1%, P<0.05). The complete patency rate of radial graft in the study group was significantly higher than that in the control group(96.4% vs. 86.0%, P<0.05), the occlusion rate was significantly lower than that in the control group(0 vs. 9.4%, P<0.05), and the stenosis rate had no significant difference between two groups. Conclusion:QFR can clarify the functional changes of coronary blood flow, select suitable anastomosis target for radial graft, reduce the occurrence of competing flow, and then improve the patency rate and clinical prognosis.

Objective:To evaluate the efficacy and safety of vedolizumab (VDZ) in the treatment of active ulcerative colitis (UC).Methods:From November 1, 2020 to October 30, 2022, at the Department of Gastroenterology, the Sixth Affiliated Hospital of Sun Yat-sen University, 81 UC patients who received VDZ treatment and completed a 14-week follow-up were retrospectively selected. The clinical data of patients, including age, disease duration, disease activity of UC were collected. The VDZ efficacy evaluation included primary and secondary efficacy indicators. The primary efficacy indicator was the clinical remission rate after 14 weeks of VDZ treatment, and the secondary efficacy indicators included the clinical response rate, steroids-free remission rate, endoscopic remission rate after 14 weeks of treatment as well as the clinical response rate, clinical remission rate, steroids-free remission rate, secondary loss of response rate after 52 weeks of treatment. The adverse reactions during the treatment were recored. Taking clinical remission after 14 weeks of treatment as the dependent variable, univariate analysis was performed to identify the risk factors affecting clinical remission of VDZ. Binary logistic regression analysis was used for multivariate analysis to determine the independent risk factors of VDZ-included clinical remission. Chi-square test and Wilcoxon signed-rank test were used for statistical analysis.Results:Among the 81 UC patients, the age was 40.0 years old (29.0 years old, 53.5 years old) and the disease duration was 42.5 months (22.5 months, 94.7 months). The proportion of patients with mild active UC was 21.0% (17/81), the proportion of patients with moderate active UC was 64.2% (52/81), and the proportion of patients with severe active UC was 14.8% (12/81). After 14 weeks of treatment, the total Mayo score decreased from baseline level of 7.0 (6.0, 9.0) to 1.0 (0.0, 3.0), and the difference was statistically significant ( Z=-6.87, P<0.001). The clinical response rate was 84.0% (68/81) and the clinical remission rate was 69.1% (56/81) after 14 weeks of treatment. Of the 17 patients treated with combination of corticosteroid therapy, 10 achieved steroid-free remission, and the endoscopic remission rate was 34.8% (23/66). Of the 43 patients followed up to 52 weeks, the total Mayo score of UC patients decreased from baseline level of 7.0 (6.0, 9.0) to 0.0 (0.0, 1.0) after 52 weeks of treatment, and the difference was statistically significant ( Z=-3.25, P<0.001). The clinical response rate was 69.8% (30/43), and the clinical remission rate was 65.1% (28/43). Of the 13 patients treated with combination of corticosteroid therapy, 10 patients achieved steroid-free remission. The secondary loss of response rate was 15.2%(5/33) .The result of the univariate analysis showed that previous use of glucocorticoids was a risk factor of clinical remission after 14 weeks of VDZ treatment ( χ2=5.88, P=0.015). The result of multivariate logistic regression analysis showed that previous use of glucocorticoids was an independent risk factor of clinical remission after 14 weeks of VDZ treatment ( OR=3.429, 95% confidence interval 1.235 to 9.517, P=0.014). During the follow-up period, 12.3% (10/81) of patients developed Clostridium difficile infections, except for 1 case stopped VDZ treatment because the clinical response was not reached, remaining 9 cases continued VDZ treatment after received anti- Clostridium difficile treatment. Conclusion:VDZ has good clinical efficacy and safety in the treatment of Chinese UC patients, and patients with no history of glucocorticoid use may be more likely to achieve clinical remission after 14 weeks of treatment.

Objectives:To evaluate the efficacy and safety of adalimumab (ADA) biosimilar in the treatment of Crohn′s disease (CD) .Methods:A retrospective cohort study was conducted. The patients with CD treated with ADA biosimilar in the Sixth Affiliated Hospital of Sun Yat-sen University from January 2019 to March 2022 with complete data were enrolled. The disease activity of patients at baseline was evaluated by Harvey-Bradshaw index (HBI) . The patients were divided into active group and remission group according to the activity. The primary endpoints were clinical response rate and remission rate at the 12th week in patients with active CD. The secondary endpoints included the clinical response rate and the remission rate in patients with active CD at the 26th week, maintenance remission rate at the 12th and the 26th weeks in patients with remission CD, and safety report.Results:Forty-eight patients were included. There were 20 patients whose HBI was 7 (6, 8) points in active group and 28 whose HBI was 3 (2, 4) points in remission group. In patients with active CD, the clinical response rate was 70.0% (14/20) and clinical remission rate was 60.0% (12/20) at the 12th week. The clinical response rate and clinical remission rate were both 61.5% (8/13) at the 26th week. The maintain remission rate of patients with remission CD was 96.4% (27/28) and 92.3% (12/13) at the 12th and the 26th weeks respectively. During the follow-up period, adverse reactions occurred in 2 patients (4.2%) and no serious adverse reaction was found.Conclusion:ADA biosimilar has good efficacy and safety in short-term induction and maintenance of clinical remission in Chinese patients with mild to moderate active CD.

Objective:To evaluate the efficacy, predictive factors, and safety of thalidomide monotherapy in the maintenance treatment of intestinal Behcet's disease.Methods:From January 2013 to March 2022, patients with intestinal Behcet's disease received thalidomide in the Sixth Affiliated Hospital of Sun Yat-sen University were retrospectively enrolled for analysis. The primary end points were the maintained steroid-free remission at 6 and 12 months. The secondary end points were the mucosal healing at 6 and 12 months, the long-term maintained steroid-free remission, predictive factors and adverse events.Results:A total of 28 patients with active intestinal Behcet's disease were enrolled. The maintained steroid-free remission at month 6, 12, 24 and 36 were 85.7%, 74.0%, 63.5% and 50.4% respectively. The median duration of maintained steroid-free remission was 49.5 (35.4, 63.6) months. Mucosal healing was 40.0% and 35.0% at month 6 and 12 respectively. Multivariate Cox regression analysis indicated that high disease activity index for intestinal Behcet's disease at baseline ( P = 0.014, HR = 1.057, 95% CI 1.011-1.104) was independently associated with lower likelihoods of maintaining steroid-free remission. During follow-up, 14 patients (50.0%) got adverse reactions and the incidence of limb numbness was 28.6%, with a median duration of 9.5 (5.5, 22.5) months. The drug dosage reduction rate was 14.3%, and the drug discontinuation rate was 17.9% due to side effects respectively. The median duration of drug discontinuation was 10.5 (23.5, 40.3) months. Conclusion:Thalidomide shows good effectiveness in maintaining long term steroid-free remission in intestinal Behcet′s disease, but the high incidence of limb numbness deserves attention.

Objectives:To evaluate the efficacy and safety of adalimumab (ADA) biosimilar in the treatment of Crohn′s disease (CD) .Methods:A retrospective cohort study was conducted. The patients with CD treated with ADA biosimilar in the Sixth Affiliated Hospital of Sun Yat-sen University from January 2019 to March 2022 with complete data were enrolled. The disease activity of patients at baseline was evaluated by Harvey-Bradshaw index (HBI) . The patients were divided into active group and remission group according to the activity. The primary endpoints were clinical response rate and remission rate at the 12th week in patients with active CD. The secondary endpoints included the clinical response rate and the remission rate in patients with active CD at the 26th week, maintenance remission rate at the 12th and the 26th weeks in patients with remission CD, and safety report.Results:Forty-eight patients were included. There were 20 patients whose HBI was 7 (6, 8) points in active group and 28 whose HBI was 3 (2, 4) points in remission group. In patients with active CD, the clinical response rate was 70.0% (14/20) and clinical remission rate was 60.0% (12/20) at the 12th week. The clinical response rate and clinical remission rate were both 61.5% (8/13) at the 26th week. The maintain remission rate of patients with remission CD was 96.4% (27/28) and 92.3% (12/13) at the 12th and the 26th weeks respectively. During the follow-up period, adverse reactions occurred in 2 patients (4.2%) and no serious adverse reaction was found.Conclusion:ADA biosimilar has good efficacy and safety in short-term induction and maintenance of clinical remission in Chinese patients with mild to moderate active CD.

Objective:To evaluate the efficacy, predictive factors, and safety of thalidomide monotherapy in the maintenance treatment of intestinal Behcet's disease.Methods:From January 2013 to March 2022, patients with intestinal Behcet's disease received thalidomide in the Sixth Affiliated Hospital of Sun Yat-sen University were retrospectively enrolled for analysis. The primary end points were the maintained steroid-free remission at 6 and 12 months. The secondary end points were the mucosal healing at 6 and 12 months, the long-term maintained steroid-free remission, predictive factors and adverse events.Results:A total of 28 patients with active intestinal Behcet's disease were enrolled. The maintained steroid-free remission at month 6, 12, 24 and 36 were 85.7%, 74.0%, 63.5% and 50.4% respectively. The median duration of maintained steroid-free remission was 49.5 (35.4, 63.6) months. Mucosal healing was 40.0% and 35.0% at month 6 and 12 respectively. Multivariate Cox regression analysis indicated that high disease activity index for intestinal Behcet's disease at baseline ( P = 0.014, HR = 1.057, 95% CI 1.011-1.104) was independently associated with lower likelihoods of maintaining steroid-free remission. During follow-up, 14 patients (50.0%) got adverse reactions and the incidence of limb numbness was 28.6%, with a median duration of 9.5 (5.5, 22.5) months. The drug dosage reduction rate was 14.3%, and the drug discontinuation rate was 17.9% due to side effects respectively. The median duration of drug discontinuation was 10.5 (23.5, 40.3) months. Conclusion:Thalidomide shows good effectiveness in maintaining long term steroid-free remission in intestinal Behcet′s disease, but the high incidence of limb numbness deserves attention.

Objective:To evaluate the efficacy and safety of vedolizumab (VDZ) in the treatment of active Crohn′s disease (CD) .Methods:A retrospective cohort study was conducted. Clinical data of 45 patients with active CD at the Sixth Affiliated Hospital of Sun Yat-sen University from November 2020 to May 2022 were analyzed. All of the patients received VDZ at the dose of 300 mg per time at 0, 2th, 6th weeks and subsequently once every 8 weeks. The clinical response and remission were evaluated by Crohn′s disease activity index (CDAI) . The endoscopic response and remission were evaluated by simple endoscopic score for Crohn′s disease (SES-CD) . All of the adverse effects occurred during the treatment of VDZ were recorded in order to evaluate the safety. The primary endpoint was the clinical remission rate at 22 weeks after treatment. The secondary endpoints included the clinical response rate at 22 weeks after treatment, the clinical response rate and clinical remission rate at 52 weeks after treatment, the endoscopic response rate and remission rate at (22 ± 8) weeks after treatment. Thirty-one patients who had previously used infliximab (IFX) and adalimumab (ADA) were set as non-Bio-Na?ve group, and 14 patients who had not previously used biologics were set as Bio-Na?ve group. The differences of the primary endpoint and some secondary endpoints between the two groups were compared.Results:At 22 weeks after treatment, the CDAI score of 45 patients decreased from baseline (261.4 ± 98.3) points to (166.6 ± 93.5) points, the difference was statistically significant ( t = 4.6, P<0.01) . Among them, 64.4% (29/45) patients achieved clinical response and 46.7% (21/45) patients achieved clinical remission. There were no significant difference in clinical response rate [71.4% (10/14) vs. 61.3% (19/31) , χ 2 = 0.4, P = 0.4] and clinical remission rate [42.9% (6/14) vs. 48.4% (15/31) , χ 2 = 0.1, P = 0.8] between the Bio-Na?ve group and non-Bio-Na?ve group at 22 weeks after treatment. At 52 weeks after treatment, the CDAI score of 33 patients decreased from baseline (306.9 ± 130.7) points to (126.6 ± 92.7) points, the difference was statistically significant ( t = 8.5, P<0.01) . Among them, 39.4% (13/33) of the patients achieved clinical response, 33.3% (11/33) of the patients achieved clinical remission, but 41.4% (12/29) of the patients had secondary loss of response. At (22 ± 8) weeks after treatment, the SES-CD score of 25 patients in active phase under endoscopy at baseline decreased from baseline 13.0 (7.0, 19.0) points to 8.0 (2.5, 18.5) points, the difference was statistically significant ( Z = -2.6, P<0.05) . Among them, 40.0% (10/25) patients achieved endoscopic response and 20.0% (5/25) patients achieved endoscopic remission. The new facial rash occurred in 1 patient (2.2%) , new joint pain in 2 (4.4%) and there was no new active tuberculosis and hepatitis B virus infection during the treatment of VDZ for 45 patients. Conclusions:Single drug of VDZ has a good effect on inducing remission in patients with mild to moderate CD and has a good safety. The previous use of IFX or ADA does not affect the efficacy of VDZ, but part of patients still have secondary loss of response.